Life Sciences manufacturers are racing against the clock to get new therapies to market as quickly as possible. The coronavirus pandemic further highlights the criticality of having strong production strategies in place. Honeywell believes manufacturers can efficiently ramp up production of potential new products to full-scale automation while still in the development phase. Parallel path automation design can start with minimum details of the final product. Use digital transformation of currently manual steps during clinical trials to prepare electronic submittals for regulatory review, and then use that data to prepare final automation design with real-time enterprise-wide visibility and predictive insights.